Pristinamycin, produced by Streptomyces pristinaespiralis, is an orally active streptogramin-like antibiotic consisting of two chemically unrelated components: Pristinamycin I (PI) and Pristinamycin II (PII). Pristinamycin is highly active against many antibiotic-resistant pathogens, particularly Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant S. aureus (VRSA) and Enterococcus faecium (VREF).
性状
Solid
体外研究(In Vitro)
In-vitro studies show pristinamycin to inhibit Staphylococci and Streptococci, including Erythromycin highly-resistant organisms, at a concentration of less than or equal to 0.78 mg/l.Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
To study Pristinamycin activity in vivo, mice infected IP with C. psittaci. Mortality in the control group was 70%. Three groups of mice received 25 mg/kg, 50 mg/kg and 100 mg/kg Pristinamycin respectively. The antibiotic was active in the 100 mg/kg dosage which is the therapeutic dosage.Medlife has not independently confirmed the accuracy of these methods. They are for reference only.